Title: Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Journal: Blood cancer journal 20180301
Title: Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Haematology 20180201
Title: The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20160801
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Journal: Molecular diagnosis & therapy 20121001
Title: Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501
Title: Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501
Title: JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Journal: Hematology (Amsterdam, Netherlands) 20120401
Title: New generation small-molecule inhibitors in myeloproliferative neoplasms.
Journal: Current opinion in hematology 20120301
Title: Incyte comes of age with JAK inhibitor approval.
Journal: Nature biotechnology 20120109
Title: The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Journal: Leukemia 20111201
Title: Targeting myeloproliferative neoplasms with JAK inhibitors.
Journal: Current opinion in hematology 20110301
Title: CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Journal: Blood 20100624
Title: Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
Journal: Bioorganic & medicinal chemistry letters 20091015
Title: CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Journal: Leukemia 20090801
Title: Pardanani A, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-1445.
Title: Monaghan KA, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia, 2011, 25(12), 1891-1899.
Title: Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240.
Title: Kitajima S, et al.Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.Cancer Cell. 2018 Sep 10;34(3):439-452.e6. doi: 10.1016/j.ccell.2018.08.009.
